Codexis, Inc.
corporate_fare Company Profile
Codexis, Inc. (NASDAQ:CDXS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 12 items for CDXS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for CDXS spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Codexis Posts $15.7M Q3 Product Revenue, Narrower $8.1M Net Loss
- Codexis Refinances Debt With $60M Trinity Capital Term Loan
- Codexis Signs siRNA Innovator to Test ECO Synthesis Platform for Stereo-Defined Fragments
- Codexis Q2 Revenue Jumps 79% on Enzyme Sales, Loss Narrows; Cash Runway Extended to 2028
- Codexis Posts Q2 2026 Revenue of $14.9M, Reaffirms Full-Year Outlook, and Pushes Cash Runway to 2028
Financial Snapshot
Short Interest & Short Volume
4.89 days to coverFINRA reported short interest of 4,398,917 shares in CDXS as of the October 30, 2026 settlement, a 11.2% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 63.1% of CDXS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CDXS, detected from its recent SEC filings · based on capital-structure filings through 2026-07-27.
Offering Terms Confirmed · Use of Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →